<div><div></div><div><span><p><span>Traws Pharma, Inc. reported results for the first quarter of 2026, posting no revenue and a net loss attributable to common stockholders of $5.69M, or diluted EPS of $(0.53), while cash on hand was $3.1M and the company said there is substantial doubt about its ability to continue without additional financing.</span></p><p><strong><span>Financial Highlights</span></strong></p><ul><li><span>Revenue was $0 for Q1 2026, down from $57K in Q1 2025.</span></li><li><span>Net loss attributable to common stockholders was $5.69M for Q1 2026, versus net income of $15.08M in Q1 2025.</span></li><li><span>Diluted earnings per share was $(0.53) for Q1 2026, compared with diluted EPS of $2.09 in Q1 2025.</span></li></ul><p><strong><span>Business Highlights</span></strong></p><ul><li><span>Cash &amp; going concern: Cash was $3.1M as of March 31, 2026, and the company disclosed substantial doubt about its ability to continue as a going concern without additional financing.</span></li><li><span>Clinical progress: Advanced Phase 2 trials for ratutrelvir and tivoxavir marboxil; Phase 2 enrollment for ratutrelvir was completed.</span></li><li><span>Regulatory: Ongoing FDA interactions for tivoxavir (pre-IND Type B and Type D meetings); the U.S. IND for tivoxavir remains on clinical hold pending resolution of toxicology matters.</span></li><li><span>Financing: In April 2026 the company executed an equity financing (pro forma structure up to $60M) to fund operations and clinical programs.</span></li><li><span>Pipeline and strategy: The portfolio includes four clinical programs across influenza, COVID-19 antivirals and oncology; oncology development is paused while pursuing business development or partnership options.</span></li></ul><p><span>Original SEC Filing: </span>Traws Pharma, Inc. [ TRAW ] - 10-Q - May. 15, 2026</p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

TRAW

LABU

<p>Traws Pharma, Inc. reported Q1 2026 results with $0 revenue and a net loss of $5.69M, or EPS of $(0.53). Cash on hand is $3.1M, raising concerns about its ability to continue without further financing. The company is advancing Phase 2 trials for its drugs and has ongoing FDA interactions. An equity financing of up to $60M was executed in April 2026 to support operations and clinical programs.</p>

TradingView

Traws Pharma

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

iShares US Pharma

VG Health

iShares Biotechnology ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Traws Pharma, Inc. 1Q 2026: Revenue $0 EPS $(0.53) — 10-Q Summary